We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing
Read MoreHide Full Article
OrthoPediatrics Corp. (KIDS - Free Report) recently introduced the OrthoPediatrics Specialty Bracing (“OPSB”) division, marking a significant advancement in non-surgical intervention for pediatric orthopedics. The company expects this new division to serve as a flagship house of brands and innovative products.
This is expected to expand the company’s total addressable market by nearly $600 million.
The Development Trajectory
The company forayed into the non-operative space following the acquisition of MD Orthopaedics (“MDO”) in 2022. With this, OrthoPediatrics gained a robust portfolio of bracing products and the Mitchell Ponseti Ankle-Foot Orthosis system for clubfoot treatment. Building on this foundation, KIDS is consistently putting efforts into developing a comprehensive portfolio of complementary products to address the large unmet needs for specialty bracing within the pediatric orthopedic market.
In this line, earlier in 2023, MDO acquired Rhino Pediatric Orthopedic Designs. The Rhino "Kicker" and "Cruiser" braces specifically target children with Developmental Dysplasia of the hip.
Added to this, OrthoPediatrics continues to diversify its non-surgical offerings with the introduction of the DF2 Brace, providing an alternative to the spica cast for femur fracture fixation in pediatric patients aged six months to five years. Recently, the company entered into a new partnership with Ora Medical, a Montreal-based firm. Together, they aim to distribute The Levity, a gait-trainer device designed to aid children with walking difficulties.
All these strategic developments align with the company's commitment to comprehensive pediatric orthopedic care.
Image Source: Zacks Investment Research
Market Prospects
Per a Market Data Library report, the global pediatric orthopedic implant market is projected to witness a robust CAGR of 10.2% from 2022 to 2031. The surge is propelled by an escalating incidence of orthopedic disorders in children, amplified awareness regarding pediatric orthopedic implants and technological strides.
Lifestyle-related orthopedic diseases are mounting, accentuating the demand for advanced therapies. Material and design innovations enhance implant safety and efficacy. Increased healthcare spending, growing awareness, digital accessibility to medical information and government initiatives fortify market expansion. The adoption of minimally invasive surgical techniques further contributes to the market's promising prospects.
Share Price Performance
Shares of KIDS have plunged 28.9% in the past year compared with the industry’s 4.9% decline.
Haemonetics’ stock has decreased 1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry’s decline of 3.3%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry’s decline of 4.7%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing
OrthoPediatrics Corp. (KIDS - Free Report) recently introduced the OrthoPediatrics Specialty Bracing (“OPSB”) division, marking a significant advancement in non-surgical intervention for pediatric orthopedics. The company expects this new division to serve as a flagship house of brands and innovative products.
This is expected to expand the company’s total addressable market by nearly $600 million.
The Development Trajectory
The company forayed into the non-operative space following the acquisition of MD Orthopaedics (“MDO”) in 2022. With this, OrthoPediatrics gained a robust portfolio of bracing products and the Mitchell Ponseti Ankle-Foot Orthosis system for clubfoot treatment. Building on this foundation, KIDS is consistently putting efforts into developing a comprehensive portfolio of complementary products to address the large unmet needs for specialty bracing within the pediatric orthopedic market.
In this line, earlier in 2023, MDO acquired Rhino Pediatric Orthopedic Designs. The Rhino "Kicker" and "Cruiser" braces specifically target children with Developmental Dysplasia of the hip.
Added to this, OrthoPediatrics continues to diversify its non-surgical offerings with the introduction of the DF2 Brace, providing an alternative to the spica cast for femur fracture fixation in pediatric patients aged six months to five years. Recently, the company entered into a new partnership with Ora Medical, a Montreal-based firm. Together, they aim to distribute The Levity, a gait-trainer device designed to aid children with walking difficulties.
All these strategic developments align with the company's commitment to comprehensive pediatric orthopedic care.
Image Source: Zacks Investment Research
Market Prospects
Per a Market Data Library report, the global pediatric orthopedic implant market is projected to witness a robust CAGR of 10.2% from 2022 to 2031. The surge is propelled by an escalating incidence of orthopedic disorders in children, amplified awareness regarding pediatric orthopedic implants and technological strides.
Lifestyle-related orthopedic diseases are mounting, accentuating the demand for advanced therapies. Material and design innovations enhance implant safety and efficacy. Increased healthcare spending, growing awareness, digital accessibility to medical information and government initiatives fortify market expansion. The adoption of minimally invasive surgical techniques further contributes to the market's promising prospects.
Share Price Performance
Shares of KIDS have plunged 28.9% in the past year compared with the industry’s 4.9% decline.
Zacks Rank and Key Picks
The stock carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Insulet (PODD - Free Report) and DexCom (DXCM - Free Report) . Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has decreased 1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry’s decline of 3.3%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry’s decline of 4.7%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.